Baricitinib
Baricitinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Diabetes Mellitus, Type 1、Long COVID、Sars-CoV-2 Infection、Coronavirus Infections。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
11 项
已进入 III/IV 期
25 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Eli Lilly and Company
- Wes Ely
- Assistance Publique - Hôpitaux de Paris
- South Valley University
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Peking Union Medical College Hospital
- Prof. Dr. Stephan Weidinger
- University of Alabama at Birmingham
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
法国、Egypt、Bangladesh、中国、德国、美国、加拿大、澳大利亚、比利时、Brazil、芬兰、Israel
正在招募患者的 Baricitinib 研究
Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
II 期招募中法国NCT06381661Baricitinib in Patients With Relapsing or naïve Dermatomyositis
III 期招募中法国NCT04972760Vitiligo, New Treatment and Serum s100B
II 期 / III 期招募中EgyptNCT06768840Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate
III 期招募中BangladeshNCT06936215Baricitinib in the Treatment of Intestinal Behçet's Syndrome
II 期招募中中国NCT06849908Molecular Signatures in Inflammatory Skin Disease
不适用招募中德国NCT03358693Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
III 期招募中美国NCT06631287RA-PRO PRAGMATIC TRIAL
III 期招募中美国加拿大NCT04692493JAK Inhibitor Dose TAPering Strategy Study
IV 期招募中法国NCT06687551ADBest TREAT Registry
不适用招募中德国NCT07904546Baricitinib for Post-HSCT Persistent Thrombocytopenia
I 期 / II 期招募中中国NCT07535645Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis
不适用招募中中国NCT07491016A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
III 期招募中美国澳大利亚比利时BrazilNCT07222137Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib
不适用招募中EgyptNCT06977035A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
III 期招募中美国Argentina澳大利亚加拿大NCT05723198Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
II 期招募中中国NCT06065046JAK Signaling in Depression and Cognition in Male Football Players
II 期招募中美国NCT07608796JAK Signaling in Depression
II 期招募中美国NCT07003997Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
I 期招募中中国NCT07554222A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
III 期招募中美国澳大利亚比利时BrazilNCT07222332Korean College of Rheumatology Biologics and Targeted Therapy Registry
不适用招募中South KoreaNCT01965132Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
III 期招募中美国NCT03414502BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis
不适用招募中荷兰NCT03549416A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
III 期招募中Argentina澳大利亚奥地利比利时NCT03773965
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。